Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Procopio

Showing results (161-170 of 289) with videos related to

Pageof 29
Sort By:
Journal of Bone Oncology|January 11, 2021
Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDEDaniele Santini, Saverio Cinieri, Donatello Gasparro, et al.
Journal of Personalized Medicine|July 29, 2023
Stability of Multi-Parametric Prostate MRI Radiomic Features to Variations in SegmentationSithin Thulasi Seetha, Enrico Garanzini, Chiara Tenconi, et al.
Therapeutic Advances in Medical Oncology|March 3, 2022
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinibSara Elena Rebuzzi, Luigi Cerbone, Alessio Signori, et al.
The Prostate|August 24, 2019
Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastasesOliver Sartor, Daniel Heinrich, Neil Mariados, et al.
Clinical Genitourinary Cancer|August 23, 2024
Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the KidneyGiulia Claire Giudice, Marco Maruzzo, Elena Verzoni, et al.
European Urology Oncology|November 4, 2024
Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel TrialAndrew J Armstrong, Noel Clarke, Mototsugu Oya, et al.
The Lancet. Oncology|February 14, 2022
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trialAntoine Thiery-Vuillemin, Johann de Bono, Maha Hussain, et al.
BJU International|February 28, 2012
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian surveyCristina Masini, Roberto Sabbatini, Camillo Porta, et al.
European Urology Oncology|October 9, 2024
Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel TrialNoel W Clarke, Andrew J Armstrong, Mototsugu Oya, et al.
Future Oncology (London, England)|December 4, 2013
Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancerSergio Bracarda, Angela Gernone, Donatello Gasparro, et al.
Pageof 29

Showing results (161-170 of 289) with videos related to

Sort By:
Pageof 29
Journal of Bone Oncology|January 11, 2021
Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDEDaniele Santini, Saverio Cinieri, Donatello Gasparro, et al.
Journal of Personalized Medicine|July 29, 2023
Stability of Multi-Parametric Prostate MRI Radiomic Features to Variations in SegmentationSithin Thulasi Seetha, Enrico Garanzini, Chiara Tenconi, et al.
Therapeutic Advances in Medical Oncology|March 3, 2022
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinibSara Elena Rebuzzi, Luigi Cerbone, Alessio Signori, et al.
The Prostate|August 24, 2019
Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastasesOliver Sartor, Daniel Heinrich, Neil Mariados, et al.
Clinical Genitourinary Cancer|August 23, 2024
Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the KidneyGiulia Claire Giudice, Marco Maruzzo, Elena Verzoni, et al.
European Urology Oncology|November 4, 2024
Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel TrialAndrew J Armstrong, Noel Clarke, Mototsugu Oya, et al.
The Lancet. Oncology|February 14, 2022
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trialAntoine Thiery-Vuillemin, Johann de Bono, Maha Hussain, et al.
BJU International|February 28, 2012
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian surveyCristina Masini, Roberto Sabbatini, Camillo Porta, et al.
European Urology Oncology|October 9, 2024
Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel TrialNoel W Clarke, Andrew J Armstrong, Mototsugu Oya, et al.
Future Oncology (London, England)|December 4, 2013
Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancerSergio Bracarda, Angela Gernone, Donatello Gasparro, et al.
Pageof 29